Universität zu Köln

Mettler, Jasmin, Mueller, Horst, Voltin, Conrad-Amadeus ORCID: 0000-0002-5437-3959, Baues, Christian, Klaeser, Bernd, Moccia, Alden, Borchmann, Peter, Engert, Andreas, Kuhnert, Georg, Drzezga, Alexander, Dietlein, Markus and Kobe, Carsten (2019). Metabolic Tumor Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma. J. Nucl. Med., 60 (2). S. 207 - 212. RESTON: SOC NUCLEAR MEDICINE INC. ISSN 1535-5667

Full text not available from this repository.

Abstract

F-18-FDG PET/CT for staging Hodgkin lymphoma may allow for accurate and reliable assessment of the metabolic tumor volume (MTV) as a baseline risk factor. Our aim was to analyze the prognostic impact of MTV measurements obtained by different means in advanced-stage Hodgkin lymphoma patients treated within the German Hodgkin Study Group HD18 trial. Methods: Within HD18, 310 patients underwent F-18-FDG PET/CT scanning for staging, which was available to the central review panel for quantitative analysis. We calculated the MTV by 4 different thresholding methods and performed receiver-operating-characteristic analysis to evaluate the potential for prediction of early response determined by PET after 2 cycles (PET-2) of dose-escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP). Logistic regression was used to evaluate its prognostic value concerning progression-free survival and overall survival. Results: All of the different MTV calculations predicted PET-2 response to a moderate and comparable degree (area under the curve, 0.62-0.63; P = 0.01-0.06). With none of the measuring methods did the receiver-operating-characteristic curves point to any unique cutoffs; rather, a wide range of possible cutoffs was indicated. None of the MTV measurements was prognostic for progression-free survival (hazard ratio, 1.2-1.5; P = 0.15-0.52) or overall survival (hazard ratio, 1.0-1.5; P = 0.95-0.27). Conclusion: Baseline MTV as determined by different means is a predictive factor for early response to eBEACOPP after 2 cycles. However, value as a prognostic factor after a highly effective PET-2-adapted treatment strategy could not be observed.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Mettler, Jasmin UNSPECIFIED UNSPECIFIED UNSPECIFIED Mueller, Horst UNSPECIFIED UNSPECIFIED UNSPECIFIED Voltin, Conrad-Amadeus UNSPECIFIED orcid.org/0000-0002-5437-3959 UNSPECIFIED Baues, Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED Klaeser, Bernd UNSPECIFIED UNSPECIFIED UNSPECIFIED Moccia, Alden UNSPECIFIED UNSPECIFIED UNSPECIFIED Borchmann, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED Kuhnert, Georg UNSPECIFIED UNSPECIFIED UNSPECIFIED Drzezga, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Dietlein, Markus UNSPECIFIED UNSPECIFIED UNSPECIFIED Kobe, Carsten UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-158252
DOI:	10.2967/jnumed.118.210047
Journal or Publication Title:	J. Nucl. Med.
Volume:	60
Number:	2
Page Range:	S. 207 - 212
Date:	2019
Publisher:	SOC NUCLEAR MEDICINE INC
Place of Publication:	RESTON
ISSN:	1535-5667
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY; ADAPTED TREATMENT; OPEN-LABEL; CHEMOTHERAPY; PHASE-3; PET/CT; SCAN Multiple languages Radiology, Nuclear Medicine & Medical Imaging Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/15825